---
figid: PMC5817855__12943_2018_804_Fig4_HTML
figlink: /pmc/articles/PMC5817855/figure/Fig4/
number: F4
caption: Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib
  mesylate)
pmcid: PMC5817855
papertitle: 'Kinase-targeted cancer therapies: progress, challenges and future directions.'
reftext: Khushwant S. Bhullar, et al. Mol Cancer. 2018;17:48.
pmc_ranked_result_index: '98450'
pathway_score: 0.7397942
filename: 12943_2018_804_Fig4_HTML.jpg
figtitle: Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib
  mesylate)
year: '2018'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5817855__12943_2018_804_Fig4_HTML.html
  '@type': Dataset
  description: Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib
    mesylate)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - WDTC1
  - Imatinib
  - ADP
  - ATP
genes:
- word: ADP
  symbol: ADP
  source: hgnc_alias_symbol
  hgnc_symbol: WDTC1
  entrez: '23038'
chemicals:
- word: Imatinib
  source: MESH
  identifier: C097613
- word: ADP
  source: MESH
  identifier: D000244
- word: ATP
  source: MESH
  identifier: D000255
diseases: []
figid_alias: PMC5817855__F4
redirect_from: /figures/PMC5817855__F4
figtype: Figure
---
